Teva to sell remaining women's health assets in 2 deals totaling $1.38B

Israel-based Teva Pharmaceuticals will sell its remaining women's health assets in two deals, totaling $1.38 billion, according to the Philadelphia Business Journal.

In one deal, Foundation Consumer Healthcare will acquire Teva's emergency contraception products, including Plan B One-Step and Next Choice One Dose, for $675 million.

Teva will sell its remaining contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million in cash.

Teva will use the money from these deals, along with proceeds from the recent $1.1 billion sale of its intrauterine device, to pay off some loan debt, according to the report.

The deals are expected to close by the end of the year.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars